Jiang Man, Zhang Xiaochun
Cancer Precision Medical Center, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, People's Republic of China.
Onco Targets Ther. 2021 Mar 2;14:1613-1621. doi: 10.2147/OTT.S293733. eCollection 2021.
A 64-year-old woman admitted to our hospital with the chief complaint of swallowing obstruction was diagnosed as relapsed small-cell carcinoma of the esophagus. Complete remission (CR) was observed after six cycles of irinotecan plus cisplatin therapy. According to the results of a next-generation sequencing analysis of the tumor specimen, anlotinib (12 mg PO q3w) was recommended. After 1 month of anlotinib treatment, the tumor decreased significantly according to computed tomography scan and gastroscopy. However, the disease progressed after 2 months of therapy. A gene analysis of the new puncture sample showed microsatellite instability and a high tumor mutation burden. Immunohistochemistry indicated positive programmed death ligand-1 expression (>1%). Because of these results, the patient was treated with anlotinib (12 mg PO q3w) in combination with toripalimab (240 mg IV drip q3w). After 3 months of therapy, CR was achieved, although progression-free survival had not been reached at the time of publication.
一名64岁女性因吞咽梗阻为主诉入院，被诊断为食管小细胞癌复发。接受六个周期的伊立替康联合顺铂治疗后观察到完全缓解（CR）。根据肿瘤标本的二代测序分析结果，推荐使用安罗替尼（口服12 mg，每3周一次）。安罗替尼治疗1个月后，根据计算机断层扫描和胃镜检查，肿瘤明显缩小。然而，治疗2个月后疾病进展。对新穿刺样本的基因分析显示微卫星不稳定和肿瘤突变负荷高。免疫组织化学表明程序性死亡配体-1表达阳性（>1%）。基于这些结果，患者接受安罗替尼（口服12 mg，每3周一次）联合特瑞普利单抗（静脉滴注240 mg，每3周一次）治疗。治疗3个月后达到CR，尽管在发表时无进展生存期尚未达到。
